logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
15/09/2025
Hong Kong Stock Exchange announcements: On September 10th, BlackRock's long position in China Pacific Insurance H Shares increased from 5.78% to 6.51%.
Latest
1 m ago
Bank of Thailand: The Thai baht remains strong driven by the surplus in the current account and the increase in gold prices.
1 m ago
Ke Liyuan: It is estimated that the construction of energy storage power station projects will be completed by 2025, with a capacity of not less than 4GWh.
1 m ago
J.P. Morgan Securities has upgraded the rating of China Bank A shares to overweight.
1 m ago
J.P. Morgan Securities has upgraded its rating on Bank of China A-shares to overweight.
2 m ago
Kanglong Huacheng announced that its wholly-owned subsidiary Kanglong Huacheng (Shaoxing) Pharmaceutical Co., Ltd. underwent a pre-approval inspection by the US Food and Drug Administration (FDA) for current Good Manufacturing Practice (cGMP) from May 29, 2025 to June 4, 2025. The inspection covered various GMP systems including quality system, material management system, production management system, equipment and facilities system, packaging and labeling system, and laboratory control system. Kanglong Shaoxing has received an on-site inspection report from the US FDA confirming that its production facilities comply with US drug cGMP quality standards and has passed the US FDA certification. This is the first time Kanglong Huacheng Shaoxing's active pharmaceutical ingredient commercial production base has passed the FDA pre-approval inspection, and following the on-site inspection by the US FDA of Kanglong Huacheng's active pharmaceutical ingredient production workshop in Ningbo in April 2025, it is also the second time that Kanglong Huacheng's active pharmaceutical ingredient production workshop in China has passed the US FDA inspection.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.